On July 28, JOINN fell 5.2% in regular trading, trading at HKD 23.78/share, with turnover of HKD 79.17 million.

The decline follows profit-taking pressure after the stock surged to the daily limit on its A-share listing and gained over 6% in Hong Kong in the prior session. The broader Life Sciences Tools & Services sector also weakened, with WuXi AppTec down 0.83%, WuXi Biologics down 1.09%, and Insilico down 7.37%, reflecting broader risk-off sentiment in the CXO space.

Market concerns over earnings quality persist. The company's first-half profit surge of 885%-1,377% year-on-year was primarily driven by approximately RMB 703-777 million in fair value gains from biological assets (experimental monkeys), while its core laboratory services business reported net profit ranging from negative RMB 142 million to positive RMB 65 million, indicating that fundamental operating profitability has yet to meaningfully recover.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)